Avalon Trust’s Novo Nordisk NVO Stock Holding History

Avalon Trust’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95.9K	Hold	2,000	–	–	0.01%	219
2026 Q1	$73.5K	Hold	2,000	–	–	0.01%	244
2025 Q4	$102K	Sell	2,000 -372	-16%	-$19K	0.01%	200
2025 Q3	$132K	Sell	2,372 -639	-21%	-$37.4K	0.01%	194
2025 Q2	$208K	Sell	3,011 -64	-2%	-$4.35K	0.02%	137
2025 Q1	$214K	Buy	3,075 +14	+0.5%	+$1.16K	0.02%	127
2024 Q4	$263K	Buy	3,061 +689	+29%	+$74.5K	0.02%	111
2024 Q3	$282K	Hold	2,372	–	–	0.02%	107
2024 Q2	$339K	Hold	2,372	–	–	0.03%	98
2024 Q1	$305K	Hold	2,372	–	–	0.03%	109
2023 Q4	$245K	Hold	2,372	–	–	0.02%	112
2023 Q3	$216K	Hold	2,372	–	–	0.02%	112
2023 Q2	$192K	Hold	2,372	–	–	0.02%	126
2023 Q1	$189K	Buy	+2,372	New	+$168K	0.02%	122

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Avalon Trust's NVO Position: Q2 2026 in Review

Avalon Trust held its Novo Nordisk (NVO) position steady in Q2 2026 at 2,000 shares worth $95.9K. The position accounts for 0.01% of the portfolio, ranked #219.

Avalon Trust first reported a position in NVO in Q1 2023 and has held it in 14 quarters since. The position peaked at $339K in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Avalon Trust held 2,000 shares of Novo Nordisk worth $95.9K as of Q2 2026.
Avalon Trust left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.01% of Avalon Trust's portfolio in Q2 2026, its #219 holding.
Avalon Trust first reported a position in Novo Nordisk in Q1 2023 and has held it in 14 quarters since.
Avalon Trust's Novo Nordisk position peaked at $339K in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Avalon Trust's 13F filing for Q2 2026, filed 6 Aug 2026.